iii
pulmonari
medicin
defin
sever
communityacquir
pneumonia
cap
sever
communityacquir
pneumonia
refer
cap
requir
manag
intens
care
unit
icu
mortal
rate
patient
sever
cap
high
empir
antimicrobi
regimen
subgroup
differ
antibiot
coverag
recommend
less
sever
case
pneumonia
ultim
decis
admit
patient
icu
must
base
clinic
judgment
howev
variou
indic
valid
predict
need
icu
admiss
supplement
clinic
decisionmak
modifi
american
thorac
societi
at
rule
defin
sever
cap
presenc
either
one
two
major
criteria
septic
shock
need
mechan
ventil
two
three
minor
criteria
systol
blood
pressur
sbp
mmhg
multilobar
pneumonia
pao
fio
british
thorac
societi
guidelin
recommend
patient
two
follow
consid
icu
admiss
alter
mental
statu
blood
urea
nitrogen
mgdl
respiratori
rate
breathsmin
either
dbp
mmhg
sbp
mmhg
curb
confus
urea
respiratori
rate
blood
pressur
pathogen
commonli
caus
sever
cap
tabl
list
common
culprit
streptococcu
pneumonia
frequent
identifi
caus
organ
pathogen
identifi
fewer
case
cultur
blood
pleural
fluid
addit
respiratori
tract
specimen
may
increas
diagnost
yield
furthermor
legionella
pneumophila
often
result
sever
ill
therefor
urinari
antigen
l
pneumophila
serogroup
measur
whether
specif
organ
identifi
appear
affect
mortal
howev
microbiolog
data
use
tailor
therapi
sputum
gram
stain
cultur
help
diagnost
cap
sputum
gram
stain
cultur
perform
noninvas
inexpens
diagnost
test
sputum
gram
stain
specimen
consid
satisfactori
interpret
neutrophil
count
per
lowpow
field
epitheli
cell
controversi
regard
result
sputum
gram
stain
influenc
clinic
practic
at
recommend
test
use
broaden
antibiot
therapi
treat
unsuspect
organ
cover
usual
empir
regimen
convers
infecti
diseas
societi
america
idsa
guidelin
suggest
empir
antimicrobi
therapi
narrow
base
sputum
gram
stain
find
keep
mind
diagnost
limit
sputum
gram
stain
cultur
includ
inabl
visual
atyp
organ
contamin
oral
flora
difficulti
encount
patient
provid
adequ
specimen
determin
select
empir
antimicrobi
therapi
patient
sever
cap
initi
empir
antibiot
regimen
depend
presenc
risk
factor
pseudomona
aeruginosa
includ
malnutrit
underli
structur
pulmonari
diseas
bronchiectasi
day
broadspectrum
antibiot
therapi
within
past
month
leukopen
rachel
h
dotson
md
jeanin
wienerkronish
md
immunosuppress
steroid
use
mg
prednison
per
day
recommend
antibiot
accord
recent
at
guidelin
list
tabl
current
idsa
guidelin
also
note
exposur
antibiot
within
preced
month
predict
resist
antibiot
class
prompt
administr
within
hour
present
appropri
empir
antibiot
strongli
encourag
studi
suggest
delay
treatment
associ
wors
outcom
risk
penicillinresist
pneumonia
pneumonia
affect
treatment
risk
factor
infect
due
penicillinresist
pneumonia
includ
age
older
year
recent
betalactam
therapi
multipl
comorbid
alcohol
immunosuppress
noninvas
diseas
contact
child
attend
day
care
sever
investig
indic
penicillinresist
pneumonia
pneumonia
absenc
mening
success
treat
betalactam
antibiot
without
advers
affect
mortal
unless
minim
inhibitori
concentr
mgl
pneumonia
resist
macrolid
fluoroquinolon
increas
clinic
failur
macrolid
rare
despit
macrolid
resist
howev
fluoroquinolon
less
potenc
pneumonia
like
ineffect
resist
strain
select
initi
empir
therapi
base
current
bacteriolog
resist
pattern
institut
altern
publish
evidencebas
practic
guidelin
may
use
obtain
cultur
respiratori
tract
specimen
identifi
pathogen
prefer
initi
antibiot
howev
administr
antibiot
therapi
delay
diagnost
test
narrow
initi
antibiot
regimen
base
quantit
cultur
result
clinic
respons
ie
deescal
avoid
excess
antibiot
use
deescal
therapi
appropri
prescrib
minim
durat
therapi
requir
efficaci
meant
deescal
antibiot
therapi
antibiot
use
promot
develop
antibiot
resist
therefor
restrict
use
antimicrobi
drug
encourag
patient
respond
favor
initi
empir
antibiot
regimen
deescal
narrow
specif
antibiot
base
result
respiratori
tract
cultur
sensit
safe
switch
patient
oral
therapi
convers
oral
therapi
may
consid
clinic
stabl
patient
demonstr
follow
improv
cough
short
breath
defervesc
f
two
roughli
onethird
onehalf
case
etilog
identifi
particular
order
antipseudomon
agent
cefepim
piperacillintazobactam
imipenem
meropenem
gener
activ
drsp
like
pathogen
popul
recommend
routin
use
unless
patient
risk
factor
p
aeruginosa
separ
measur
hour
apart
white
blood
cell
count
trend
toward
normal
satisfactori
oral
intak
gastrointestin
tract
absorpt
major
patient
receiv
appropri
therapi
show
favor
clinic
respons
within
hour
therefor
initi
antibiot
therapi
chang
within
hour
initi
unless
indic
signific
clinic
worsen
microbiolog
data
rememb
certain
host
factor
advanc
age
alcohol
chronic
obstruct
pulmonari
diseas
copd
associ
delay
resolut
despit
appropri
treatment
radiograph
resolut
pneumonia
lag
behind
clinic
improv
case
may
take
week
clear
complet
discuss
potenti
reason
patient
may
respond
favor
empir
therapi
clinic
deterior
lack
respons
empir
antimicrobi
therapi
within
day
often
indic
treatment
failur
warrant
thorough
reassess
addit
investig
follow
consid
health
careassoci
pneumonia
hcap
term
hcap
refer
pneumonia
develop
patient
live
nurs
home
longterm
care
facil
undergo
hemodialysi
receiv
iv
antimicrobi
therapi
chemotherapi
wound
care
within
preced
day
hospit
least
day
within
preced
day
caus
pathogen
patient
similar
respons
hospitalacquir
pneumonia
ventilatorassoci
pneumonia
vap
often
multidrug
resist
major
case
due
microaspir
pathogen
colon
oropharynx
endotrach
intub
interfer
normal
host
defens
impair
patient
abil
cough
disrupt
protect
barrier
oropharynx
trachea
bacterialaden
oropharyng
secret
pool
leak
around
cuff
endotrach
tube
infect
lower
respiratori
tract
facilit
patient
supin
hypothes
endotrach
tube
colon
bacteria
encas
biofilm
tube
manipul
suction
result
embol
bacteria
lower
respiratori
tract
less
common
sourc
bacteria
includ
paranas
sinus
dental
plaqu
gastrointestin
tract
rare
hematogen
spread
anoth
site
infect
bronchoscop
method
includ
bronchoalveolar
lavag
protect
specimen
brush
nonbronchoscop
method
perform
intub
patient
respiratori
therapist
includ
minibronchoalveolar
lavag
protect
telescop
cathet
bronchoscop
nonbronchoscop
method
similar
perform
characterist
howev
diagnost
threshold
procedur
vari
although
nonbronchoscop
procedur
perform
blindli
frequent
sampl
right
lower
lobe
studi
shown
vap
diffus
process
typic
involv
everi
pulmonari
lobe
particularli
posterior
lower
lobe
advantag
quantit
cultur
lower
respiratori
tract
specimen
clinic
approach
diagnosi
vap
microbiolog
diagnosi
use
quantit
cultur
lower
respiratori
tract
specimen
establish
presenc
lung
infect
also
identifi
etiolog
organ
sever
studi
shown
unless
antibiot
therapi
initi
chang
within
hour
preced
sampl
antibiot
safe
discontinu
quantit
cultur
lavag
specimen
diagnost
threshold
qualit
semiquantit
cultur
trachea
rare
yield
neg
result
due
tracheal
colon
even
absenc
lung
infect
multicent
random
control
trial
patient
meet
clinic
criteria
vap
show
diagnost
strategi
involv
bronchoscop
sampl
quantit
cultur
result
significantli
less
antibiot
use
decreas
mortal
compar
clinic
diagnost
strategi
use
qualit
cultur
endotrach
aspir
factor
predispos
patient
nosocomi
lung
infect
drugresist
organ
hospitalacquir
pneumonia
hap
vap
develop
within
first
hospit
day
describ
earlyonset
patient
risk
infect
drugresist
pathogen
hap
vap
develop
day
hospit
ie
lateonset
within
preced
month
patient
hospit
receiv
antibiot
addit
risk
factor
multidrugresist
pathogen
list
tabl
consid
prescrib
empir
therapi
nosocomi
pneumonia
determin
select
initi
empir
antibiot
therapi
hap
hcap
vap
investig
shown
earli
appropri
mean
effect
etiolog
pathogen
antimicrobi
therapi
vap
improv
outcom
at
guidelin
recommend
empir
therapi
initi
select
antibiot
depend
whether
patient
risk
factor
drugresist
nosocomi
pathogen
whether
pneumonia
classifi
earlyor
lateonset
individu
institut
differ
pattern
antimicrobi
resist
therefor
mani
hospit
antibiot
guidelin
antibiogram
empir
therapi
base
like
pathogen
local
antimicrobi
resist
pattern
patient
receiv
antibiot
recent
empir
therapi
includ
antimicrobi
differ
class
patient
receiv
tabl
durat
antimicrobi
therapi
hap
hcap
vap
prospect
random
clinic
trial
treatment
strategi
cultureproven
vap
result
signific
decreas
multidrugresist
bacteria
antibioticfre
day
differ
mortal
icu
length
stay
mechan
ventilatorfre
day
compar
regimen
higher
rate
recurr
document
regimen
infect
due
acinetobact
pseudomona
speci
therefor
vap
due
organ
treat
day
infect
pathogen
similar
hap
hcap
treat
similarli
extend
therapi
day
may
indic
set
multilobar
diseas
cavit
malnutrit
necrot
gramneg
infect
combin
antibiot
therapi
